Congratulations Wilba for providing a most informative link……may I expand the discussion by commenting on its significance ?
@Sector You correctly pointed out that I had chastised the ASX for having the attention span of a gnat. You were also quick to point out the dire performance of Mesoblast since I made my observation…..although my observation that the market was ignoring the data, did not suggest that the price would go up before some form of news came out…so I do not see why my observation is invalid.
The fact is Sector , you still don’t have a clue …but Roberto Bolli does.
Let me introduce you to him ….courtesy of a another recent publication whose authors paid tribute to his work with the linked dedication shown below.
As you can see below..Professor Bolli spent the best part of ten years as the distinguished Editor of CirculationResearch, one of the top 5 most prestigious cardiology journals in the world …it also happens to be the official journal of the AmericanHeartAssociation. Bolli was funded by the NIH to review the meta data concerning the use of mesenchymal cells…his findings were published a few weeks ago…and I think they will send reverberations all around the FDA . He was also joined in his sector overview, by another colleague, Dr Xian-Laing Tang, who is also an Assoc Prof at Harvard Medical School. Now I don’t suppose many of you have had the time or attention span to read their research findings..but you should …because they vindicate virtually everything that Prof Itescu has asserted for the last few years.
Bolli, after 40 years as a research scientist and leading authority in peer reviewed cardiovascular medicine and has a reputation virtually second to none in providing painstaking rigorous analysis of randomised controlled studies . HIs conclusions after studying every important RCT in the MSC space…
“the mantra that clinicaltrials of celltherapy for HF have been "disappointing" continues to berepeated in the literature.There is only one problem - it's nottrue. In fact, as pointed out in a recent reviewl-, several Phase Il/1II, double-blind,randomized, multicenter clinical trials have revealed substantial beneficial effects of cell therapy in HF. In the setting ofischemic HF, these include ixCELL-DCM|(30], MSC-HF[3I], CONCERT-HF|32], DREAM-HF(33,34], and TAC-HFT(35]. The benefitsof cell therapy range from a 6.2 units increase in left ventricular ejection fraction in MSC-HF to an improvement in quality of life (measured by MLHFQ score) and 6 minute walk difference (TAC-HFT) and to a reduction in major cardiac events (MACE) by 37% (ixCELL-DCM),77%(CONCERT-HF) and 33%-65% (depending on the type of MACE) in Mesoblasts DREAM-HF. Certainly, these trials are notdisappointing , nor are the aforementioned salubrious effects “minor” or “incremental”. In fact, considering that the treatment was given only once and the outcome measured 12 months later , the effects are quite remarkable. Those who deny it should name another therapy that produces any measurable change in clinical status in HF patients 12 months after one dose. It is time for this widespreadmisrepresentation to be rectified.”
So , to all the teenage scribblers out there who think @otherperspective is full of waffle and no substance , I repeat Prof Bolli’s challenge …FIND SOMETHING ELSE BETTER….. because the lead Editor of the AHA premier publication says he has not seen anything more promising. What is happening to companies like Mesoblast right now …is an absolute disgrace. Bolli’s publication is a shot across the bow to the FDA …heads will roll if the prevarication continues…because there are 6m Americans currently suffering from CHF who might be starting to think about a real class action ..against the sheer incompetence of the FDA. The overwhelming efficacy of MSCs has already caused a Cardiology Panel of the FDA , looking at Mesoblasts CHF phase 3 results ,to comment that there might be an ethical dilemma in not allowing use of MSC therapy, while they have been approving far less efficacious therapies withmajorsideeffects . Bolli would appear to agree.
I try to remain calm while I read the garbage coming from so many shorters on this forum. They would like to perpetuate the most vile agenda …to stop therapies which could save the lives of millions of people getting to market….but a constant programme of harassment and disingenuous commentary, which completely ignores the data ….is apparently correct because the share price has gone down . SELL LOW, BUY HIGH …they must be laughing all the way to the bank.
Meanwhile, analysts from the like of Dawson James and HC Wainwright who specialise in the sector , have just revised their numbers according to TipRanks and have strong buy recommendations both with a US$16 ADR price target for MESO. It really is pathetic that we are at a fraction of our true worth. I suspect that SIlviu will be submitting his BLA application in the next 3-6 weeks …just watch the stock when it finally happens. OP
DYOR. Do not rely on any opinion or fact disclosed in this article when making an investment decision.
MSB Price at posting:
99.0¢ Sentiment: Buy Disclosure: Held
(20min delay)